13.60
Intellia Therapeutics Inc stock is traded at $13.60, with a volume of 4.11M.
It is up +6.38% in the last 24 hours and up +42.21% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.78
Open:
$12.82
24h Volume:
4.11M
Relative Volume:
0.90
Market Cap:
$1.41B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.4808
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+12.73%
1M Performance:
+42.21%
6M Performance:
+23.70%
1Y Performance:
-48.54%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
13.60 | 1.32B | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Mar-05-25 | Initiated | H.C. Wainwright | Buy |
Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Apr-13-23 | Initiated | Canaccord Genuity | Buy |
Mar-21-23 | Initiated | Bernstein | Outperform |
Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Sep-01-22 | Initiated | Citigroup | Sell |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Jun-16-22 | Initiated | BofA Securities | Buy |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Feb-18-22 | Initiated | William Blair | Outperform |
Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-22 | Initiated | Cowen | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
Oct-05-21 | Initiated | Guggenheim | Buy |
Sep-24-21 | Initiated | Stifel | Buy |
Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
Jun-11-21 | Initiated | H.C. Wainwright | Buy |
May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-27-20 | Initiated | Truist | Buy |
Oct-14-20 | Initiated | Wells Fargo | Overweight |
Sep-18-20 | Initiated | Goldman | Buy |
Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-09-19 | Initiated | Robert W. Baird | Outperform |
Jun-10-19 | Initiated | ROTH Capital | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
Oct-29-18 | Initiated | Credit Suisse | Neutral |
Sep-21-18 | Initiated | Raymond James | Mkt Perform |
May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
Nov-01-17 | Reiterated | Jefferies | Buy |
Jun-22-17 | Resumed | Jefferies | Buy |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
NTLA CFO Sells 7,462 Shares in Tax Withholding Transaction – Form 4 | YGMZ SEC FilingForm 6-K - Stock Titan
What analysts say about Intellia Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional
What makes Intellia Therapeutics Inc. stock attractive to long term investorsHigh-yield capital appreciation - jammulinksnews.com
Is Intellia Therapeutics Inc. a good long term investmentExtraordinary earning power - Autocar Professional
What drives Intellia Therapeutics Inc. stock priceFree Investment Community - Autocar Professional
Will Intellia Therapeutics Inc. stock benefit from interest rate changesHigh-yield capital appreciation - jammulinksnews.com
How high can Intellia Therapeutics Inc. stock price go in 2025Accelerated financial growth - jammulinksnews.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options - Nasdaq
Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Intellia Bets On CRISPR Breakthroughs Despite A Rocky Year - Finimize
ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest
Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st
Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan
Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq
Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey
Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Zacks Investment Research
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):